{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T19:10:53Z","timestamp":1793214653124,"version":"4.5.0"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,9]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>The aim of this study was to evaluate the efficacy of topical interferon (IFN) therapy in pseudophakic cystoid macular edema (P-CME).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This is a prospective, interventional case series of patients with P-CME. Patients presenting with P-CME were given the option of topical IFN therapy against conventional treatment with oral, topical, intravitreal, and periocular steroid therapy and antivascular growth factors. Patients who consented for the same were advised to use the IFN drops four times\/day. Commercially available injection IFN alfa-2b was reconstituted to prepare the eye drops (1 MIU\/ml). Optical coherence tomography (OCT) was done at the baseline and on each review visit until complete resolution of P-CME.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Eight eyes of eight patients diagnosed with P-CME were studied. Mean central macular thickness (CMT) on OCT at the presentation (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 8) and at 4 weeks post topical IFN therapy (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 6) was 560.1 \u03bcm (range: 349\u2013702 \u03bcm) and 344.33 \u03bcm (range: 250\u2013390 \u03bcm), respectively. All eyes except one had posterior capsular rent (PCR). Five patients had regular follow-up until resolution. The mean duration of complete first resolution of P-CME was 5 weeks (range: 4\u20137.1 weeks) in those patients. Relapse was seen in three patients who responded after resuming or continuing the therapy. Case 1 had 9 months follow-up after completion of IFN therapy, and no recurrence was noted. No ocular or systemic side effects related to the topical IFN therapy were noted clinically, except papillary conjunctivitis in one patient.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Topical IFN therapy can be a noninvasive, economical, and effective choice of treatment for P-CME, especially in the case of PCR, and where steroids are contraindicated.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ijo.ijo_2704_20","type":"journal-article","created":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T23:07:16Z","timestamp":1630537636000},"page":"2355-2360","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":17,"title":["Topical interferon \u2013 A novel treatment for pseudophakic macular edema"],"prefix":"10.4103","volume":"69","author":[{"given":"Ankush","family":"Kawali","sequence":"first","affiliation":[{"name":"Department of Uveitis and Ocular Immunology, Narayana Nethralaya, Bangalore, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ram","family":"Snehith","sequence":"additional","affiliation":[{"name":"Department of Vitreo-Retina, Narayana Nethralaya, Bangalore, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivek","family":"Singh","sequence":"additional","affiliation":[{"name":"Department of Vitreo-Retina, Narayana Nethralaya, Bangalore, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srinivasan","family":"Sanjay","sequence":"additional","affiliation":[{"name":"Department of Uveitis and Ocular Immunology, Narayana Nethralaya, Bangalore, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Padmamalini","family":"Mahendradas","sequence":"additional","affiliation":[{"name":"Department of Uveitis and Ocular Immunology, Narayana Nethralaya, Bangalore, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohit","family":"Shetty","sequence":"additional","affiliation":[{"name":"Department of Refractive Surgeries, Narayana Nethralaya, Bangalore, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,8,25]]},"reference":[{"key":"B1-20240828","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1016\/S0886-3350(03)00233-5","article-title":"Treatment of acute pseudophakic cystoid macular edema:Diclofenac versus ketorolac","volume":"29","author":"Rho","year":"2003","journal-title":"J Cataract Refract Surg"},{"key":"B2-20240828","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD004239.pub3","article-title":"Non-steroidal anti-inflammatory agents for treating cystoid macular oedema following cataract surgery","author":"Sivaprasad","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"B3-20240828","first-page":"235","article-title":"Intravitreal bevacizumab for pseudophakic cystoid macular edema;a systematic review","volume":"7","author":"Ghasemi Falavarjani","year":"2012","journal-title":"J Ophthalmic Vis Res"},{"key":"B4-20240828","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1097\/IAE.0000000000002465","article-title":"Evaluation of the effect of topical interferon a2b as a complementary treatment of macular edema of patients with diabetic retinopathy:A double-blind placebo-controlled randomized clinical trial study","volume":"40","author":"Afarid","year":"2020","journal-title":"Retina"},{"key":"B5-20240828","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.ajoc.2018.03.005","article-title":"Topical interferon alpha 2b in the treatment of refractory pseudophakic cystoid macular edema","volume":"10","author":"Maleki","year":"2018","journal-title":"Am J Ophthalmol Case Rep"},{"key":"B6-20240828","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1001\/archophthalmol.2011.3","article-title":"Long-term efficacy and safety of low-dose and dose-escalating interferon alfa-2a therapy in refractory Beh\u00e7et uveitis","volume":"129","author":"Onal","year":"2011","journal-title":"Arch Ophthalmol"},{"key":"B7-20240828","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1136\/bjo.2004.061119","article-title":"Interferon as a treatment for uveitis associated with multiple sclerosis","volume":"89","author":"Becker","year":"2005","journal-title":"Br J Ophthalmol"},{"key":"B8-20240828","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ajo.2007.03.050","article-title":"Interferon-alpha as an effective treatment for noninfectious posterior uveitis and panuveitis","volume":"144","author":"Plskova","year":"2007","journal-title":"Am J Ophthalmol"},{"key":"B9-20240828","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1097\/01.iae.0000244265.75771.71","article-title":"Interferon alfa-2a:A new treatment option for long lasting refractory cystoid macular edema in uveitis?A pilot study","volume":"26","author":"Deuter","year":"2006","journal-title":"Retina"},{"key":"B10-20240828","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1128\/CMR.14.4.778-809.2001","article-title":"Antiviral actions of interferons","volume":"14","author":"Samuel","year":"2001","journal-title":"Clin Microbiol Rev"},{"key":"B11-20240828","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1080\/09273948.2019.1585883","article-title":"Interferon alpha for refractory pseudophakic cystoid macular edema (Irvine-gass syndrome)","volume":"28","author":"Dimopoulos","year":"2020","journal-title":"Ocul Immunol Inflamm"},{"key":"B12-20240828","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1136\/bjo.82.3.323","article-title":"Interferon associated retinopathy","volume":"82","author":"Hayasaka","year":"1998","journal-title":"Br J Ophthalmol"},{"key":"B13-20240828","doi-asserted-by":"crossref","first-page":"209","DOI":"10.21037\/hbsn.2015.12.14","article-title":"Ophthalmological side effects of interferon therapy of chronic hepatitis C","volume":"5","author":"Medhat","year":"2016","journal-title":"Hepatobiliary Surg Nutr"},{"key":"B14-20240828","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1001\/archophthalmol.2011.385","article-title":"Topical interferon Alfa-2b for management of ocular surface squamous neoplasia in 23 cases:Outcomes based on American Joint Committee on cancer classification","volume":"130","author":"Shah","year":"2012","journal-title":"Arch Ophthalmol"},{"key":"B15-20240828","first-page":"185","article-title":"Intravitreal interferon alpha-2b for the treatment of neovascular age-related macular degeneration:A pilot study","volume":"32","author":"Kertes","year":"1997","journal-title":"Can J Ophthalmol"},{"key":"B16-20240828","doi-asserted-by":"crossref","first-page":"873","DOI":"10.3389\/fimmu.2017.00873","article-title":"The role of interferons in inflammation and inflammasome activation","volume":"8","author":"Kopitar-Jerala","year":"2017","journal-title":"Front Immunol"},{"key":"B17-20240828","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.3389\/fphar.2018.01368","article-title":"IFN-b plays both pro- and anti-inflammatory roles in the rat cardiac fibroblast through differential STAT protein activation","volume":"9","author":"Bol\u00edvar","year":"2018","journal-title":"Front Pharmacol"},{"key":"B18-20240828","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1038\/sj.gt.3301179","article-title":"Anti-inflammatory action of type I interferons deduced from mice expressing interferon b","volume":"7","author":"Bosc\u00e1","year":"2000","journal-title":"Gene Ther"},{"key":"B19-20240828","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1093\/jnci\/95.6.437","article-title":"Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis","volume":"95","author":"Von Marschall","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"B20-20240828","doi-asserted-by":"crossref","first-page":"e19618","DOI":"10.1371\/journal.pone.0019618","article-title":"Interferon-a\/b and anti-fibroblast growth factor receptor 1 monoclonal antibody suppress hepatic cancer cells in vitro and in vivo","volume":"6","author":"Sasaki","year":"2011","journal-title":"PLoS One"},{"key":"B21-20240828","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1182\/blood.V82.8.2371.2371","article-title":"Type-I interferons are potent inhibitors of interleukin-8 production in hematopoietic and bone marrow stromal cells","volume":"82","author":"Aman","year":"1993","journal-title":"Blood"}],"container-title":["Indian Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijo.IJO_2704_20","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T19:33:46Z","timestamp":1786736026000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijo.IJO_2704_20"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,25]]},"references-count":21,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.4103\/ijo.ijo_2704_20","relation":{},"ISSN":["0301-4738","1998-3689"],"issn-type":[{"value":"0301-4738","type":"print"},{"value":"1998-3689","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,25]]},"assertion":[{"value":"2020-08-20","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-04-24","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}